Chandan Healthcare Ltd (CHANDAN) — shareholding pattern, promoter holding, financials and share price
About Chandan Healthcare Ltd (CHANDAN)
Chandan Healthcare Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as CHANDAN and on the BSE under scrip code 91069. Its ISIN is INE0B2N01016.
Incorporated in September 2003, Chandan Healthcare Limited runs diagnostic centers in North India with pathology and radiology testing services. [1]
Chandan Healthcare Limited operates an integrated diagnostics, radiology and retail pharmacy network primarily across North and Central India, running company-owned labs and diagnostic centres with NABL/NABH accreditations and a digital front-end called Chandan 24x7 for appointments, e-pharmacy and patient records.
In Q3 FY26 Chandan reported consolidated Total Income of ₹65.77 crore (up ~20% YoY) and EBITDA of ₹12.61 crore with a 263 bps expansion in EBITDA margin to 19.17%; nine‑month results show sustained improvement with 9M FY26 Total Income ₹203.27 crore and EBITDA margin rising to 20.95%.
Listed peers in Healthcare Service Provider: Health X Platform Ltd, 3B Blackbio DX Ltd, Gaudium IVF and Women Health Ltd, Vaidya Sane Ayurved Laboratories Ltd, Star Imaging and Path Lab Ltd, Vijaypd Ceutical Ltd.
Valuation & Returns
10 Jul 2026At ₹249.65 a share on 10 Jul 2026, Chandan Healthcare Ltd (CHANDAN) was valued at a price-to-earnings ratio of 23.13x against an industry P/E of 61.73x and a price-to-book of 4.98x on a book value of ₹50.14 per share as of Mar 2025. Solomo computes return on equity of 21.52% and return on capital employed of 24.35% from filed results. Earnings ratios use consolidated results for the twelve months Mar 2025 to Mar 2026.
- P/E
- 23.13x
- Industry P/E
- 61.73x
- P/B
- 4.98x
- EPS (TTM)
- ₹10.79
- Book value / share
- ₹50.14
- ROE
- 21.52%
- ROCE
- 24.35%
- ROA
- 12.53%
- Debt / equity
- 0.39x
- Dividend yield
- 0%
- EBITDA margin
- 19.51%
- 52-week range
- ₹185.4 – ₹358
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Chandan Healthcare Ltd (CHANDAN) reported revenue of ₹276 crore, net profit of ₹27 crore and earnings per share of ₹11.07. That compares with revenue of ₹230 crore and net profit of ₹24 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹75.58 crore and net profit ₹6.92 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 120 | 137 | 177 | 230 | 276 |
| Net profit (₹ cr) | -1 | 3 | 16 | 24 | 27 |
| EPS (₹) | -0.56 | 1.68 | 8.14 | 9.07 | 11.07 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 14.18% | 21.73% | 30.31% |
| Profit growth | 70.91% | - | 43.77% |
| Stock price CAGR | - | - | 22% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 49.61% of Chandan Healthcare Ltd (CHANDAN) (up 0.06 pp QoQ). Market capitalisation was ₹610 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2025.
Largest disclosed public shareholders in Jun 2026: NEGEN UNDISCOVERED VALUE FUND 3.16%, SHWETA LAMBA 1.72%, ANANT WEALTH CONSULTANTS 1.63%, HARI SHANKER DIXIT 1.43%, SHALU AGGARWAL 1.42%, AMIT SRIVASTAVA 1.4%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 49.61% | - | - | - | - |
| Mar 2026 | 49.55% | - | - | - | - |
| Dec 2025 | 49.47% | - | - | - | - |
| Sep 2025 | 49.47% | - | - | - | - |
| Mar 2025 | 49.43% | - | - | - | - |